Peri-operative and Post-operative Management of Hemophiliac Patients with Inhibitors

  • Elena Santagostino
  • Maria Elisa Mancuso


In the past, elective orthopedic surgery in hemophilic patients with inhibitors was usually not contemplated because of the high risk of bleeding complications. Thanks to the progress made in the development of bypassing therapies, elective surgery has become feasible; however, only centers that are already experienced can tackle this challenge. A strict collaboration amongst surgeons, hematologists, and physiotherapists is essential for a successful long-term outcome.


Recombinant Factor VIIa Inhibitor Titer Factor VIII Inhibitor Immune Tolerance Induction Elective Orthopedic Surgery 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aledort LM (2004) Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypassing activity. J Thromb Haemost 2:1700–1708PubMedCrossRefGoogle Scholar
  2. 2.
    Abshire T, Kenet G (2004) Recombinant factor VIIa: review of afficacy, dosing regimens and safety in patients with congenital and acquired factor VIII and IX inhibitors. J Thromb Haemost 2:899–909PubMedCrossRefGoogle Scholar
  3. 3.
    Ehrlich HJ, Henzl MJ, Gomperts ED (2002) Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 8:83–90PubMedCrossRefGoogle Scholar
  4. 4.
    White GC II, Rosendaal F, Aledort LM et al (2001) Recommendations of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 85:560PubMedGoogle Scholar
  5. 5.
    Gringeri A, Mannucci PM (2005) Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 11:611–619PubMedCrossRefGoogle Scholar
  6. 6.
    Hay CR, Baglin TP, Collins PW et al (2000) The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO). Br J Haematol 111:78–90PubMedCrossRefGoogle Scholar
  7. 7.
    Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P and the Members of the French FEIBA Study Group (1997) Multicenter retrospective study on the utilisation of Feiba in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 77:1113–1119PubMedGoogle Scholar
  8. 8.
    Tjonnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR (2004) Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 10:174–178PubMedCrossRefGoogle Scholar
  9. 9.
    Shapiro AD, Gilchrist GS, Hoots WK et al (1998) Prospective randomised trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80:773–778PubMedGoogle Scholar
  10. 10.
    Santagostino E, Morfini M, Rocino A et al (2001) Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 86:954–958PubMedGoogle Scholar
  11. 11.
    Smith MP, Ludlam CA, Collins PW et al (2001) Elective surgery on factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII: plasma factor VII activity of 10 IU/ml is associated with an increased incidence of bleeding. Thromb Haemost 86:949–953PubMedGoogle Scholar
  12. 12.
    Ludlam CA, Smith MP, Morfini M et al (2003) A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 120:808–813PubMedCrossRefGoogle Scholar
  13. 13.
    Hoffman M, Monroe DM 3rd, Roberts HR (1998) Activated factor VII activates factor IX and X on the surface of activated platelets: thoughts on the mechanism of action of highdose activated factor VII. Blood Coagul Fibrinolysis 9(Suppl 1):S61–65PubMedGoogle Scholar
  14. 14.
    Butenas S, Brummel KE, Bouchard BA, Mann KG (2003) How factor VIIa works in hemophilia. J Thromb Haemost 1:1158–1160PubMedCrossRefGoogle Scholar
  15. 15.
    Nilsson IM, Jonsson S, Sundqvist SB et al (1981) A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood 58:38–44PubMedGoogle Scholar
  16. 16.
    Kroner BL (1999) Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 77(Suppl 1):33–37PubMedCrossRefGoogle Scholar
  17. 17.
    Rodríguez-Merchán EC, Rocino A, Ewenstein B et al (2004) Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 10(Suppl 2):50–52PubMedCrossRefGoogle Scholar
  18. 18.
    Solimeno LP, Perfetto OS, Pasta G, Santagostino E (2006) Total joint replacement in patients with inhibitors. Haemophilia 12(Suppl 3):113–116PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Elena Santagostino
    • 1
  • Maria Elisa Mancuso
    • 2
  1. 1.Hemophilia Outpatient Clinic, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical SpecialtiesIRCCS Maggiore Hospital, Mangiagalli and Regina Elena FoundationMilanItaly
  2. 2.Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Internal Medicine and Medical Specialties, IRCCS Maggiore HospitalMangiagalli and Regina Elena FoundationMilanItaly

Personalised recommendations